Nerve Growth Factor Pathobiology During The Progression Of Alzheimer's Disease

Elliott J. Mufson  
*Barrow Neurological Institute*, elliott.mufson@dignityhealth.org

Scott E. Counts

Stephen D. Ginsberg

Laura Mahady

Sylvia E. Perez

See next page for additional authors

Follow this and additional works at: [https://scholar.barrowneuro.org/neurobiology](https://scholar.barrowneuro.org/neurobiology)

**Recommended Citation**

[https://scholar.barrowneuro.org/neurobiology/335](https://scholar.barrowneuro.org/neurobiology/335)
Authors
Elliott J. Mufson, Scott E. Counts, Stephen D. Ginsberg, Laura Mahady, Sylvia E. Perez, Stephen M. Massa, Frank M. Longo, and Milos D. Ikonomovic
Nerve Growth Factor Pathobiology During the Progression of Alzheimer’s Disease

Elliott J. Mufson1*, Scott E. Counts2, Stephen D. Ginsberg3,4, Laura Mahady1, Sylvia E. Perez1, Stephen M. Massa5, Frank M. Longo6 and Milos D. Ikonomovic7

1 Department of Neurobiology and Neurology, Department of Neurobiology, and Department of Neurological Sciences, Alzheimer’s Disease Laboratory, Barrow Neurological Institute, St. Joseph’s Medical Center, Phoenix, AZ, United States,
2 Translational Science and Molecular Medicine Michigan State University College of Human Medicine, Grand Rapids, MI, United States, 3 Center for Dementia Research, Nathan Kline Institute, Orangeburg, NY, United States, 4 Department of Psychiatry, Department of Neuroscience, and Physiology and NYU Neuroscience Institute, New York University Langone Medical Center, New York, NY, United States, 5 Department of Neurology, San Francisco VA Health Care System, University of California, San Francisco, San Francisco, CA, United States, 6 Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, United States, 7 Department of Neurology and Department of Psychiatry, Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA, United States

The current review summarizes the pathobiology of nerve growth factor (NGF) and its cognate receptors during the progression of Alzheimer’s disease (AD). Both transcript and protein data indicate that cholinotrophic neuronal dysfunction is related to an imbalance between TrkA-mediated survival signaling and the NGF precursor (proNGF)/p75NTR-mediated pro-apoptotic signaling, which may be related to alteration in the metabolism of NGF. Data indicate a spatiotemporal pattern of degeneration related to the evolution of tau pathology within cholinotrophic neuronal subgroups located within the nucleus basalis of Meynert (nbM). Despite these degenerative events the cholinotrophic system is capable of cellular resilience and/or plasticity during the prodromal and later stages of the disease. In addition to neurotrophin dysfunction, studies indicate alterations in epigenetically regulated proteins occur within cholinotrophic nbM neurons during the progression of AD, suggesting a mechanism that may underlie changes in transcript expression. Findings that increased cerebrospinal fluid levels of proNGF mark the onset of MCI and the transition to AD suggests that this proneurotrophin is a potential disease biomarker. Novel therapeutics to treat NGF dysfunction include NGF gene therapy and the development of small molecule agonists for the cognate prosurvival NGF receptor TrkA and antagonists against the pan-neurotrophin p75NTR death receptor for the treatment of AD.

Keywords: Alzheimer, nerve growth factor, mild cognitive impairment, epigenetics, neurotrophin receptors, biomarker

INTRODUCTION

Alzheimer’s disease (AD) is a progressive and fatal age-associated brain disorder characterized clinically by memory decline, impairment of activities of daily living, neuropsychiatric symptoms, and other behavioral disturbance. Prevalence reports indicate that approximately 18 million people have AD worldwide, with > 5.8 million people in the United States (Alzheimer’s Association, 2019).
The percentage of cases increases twofold with approximately every 5 years of an increase in age, indicating that 1% of individuals 60 years of age and approximately 30% of people 85 years of age will exhibit the disease. Lacking significant intervention, the number of symptomatic people in the United States will increase to 13.8 million by midcentury (2019). The cost of caring for those with AD will exceed 100 billion United States dollars yearly (Christensen, 2007; Wimo, 2007; Wimo et al., 2017). These alarming statistics stress the overwhelming importance of developing effective treatments for use in the early or prodromal stages of AD.

PRODROMAL AD

Alzheimer’s disease has an extensive preclinical stage, possibly as early as 15–20 years before the onset of clinical symptoms (Sperling et al., 2014) (Figure 1). Mild cognitive impairment (MCI), a term now synonymous with prodromal AD, is an intermediate phase between normal brain aging and frank dementia when neurofibrillary tangles (NFTs) and amyloid-beta peptide (Aβ) lesions are increased in comparison to those with no cognitive impairment (NCl) (Guillozet et al., 2003; Markesbery et al., 2006; Markesbery, 2010). MCI as a clinical concept was developed from memory clinics, which evaluated milder demented subjects from longitudinal investigations of older cohorts who were tested annually for cognitive status. Such investigations demonstrated that many with earlier, milder cognitive decline failed to show impairment in two cognitive domains as required for an NINDS/ADRDA AD diagnosis (McKhann et al., 1984). These people were defined with an amnestic disorder and termed amnestic MCI (aMCI) (Petersen et al., 1999). Although memory clinics suggested that aMCI was the more common type of MCI leading to AD, it was evident that this entity comprised a minor but a significant aspect of this clinical classification. Overall, the clinical diagnosis of MCI encompasses a heterogeneous population of patients that includes those with isolated memory problems, classified as single domain aMCI, while those with a memory deficit and other cognitive domain impairments are categorized as multi-domain MCI (mdMCI) (Petersen, 2004; Johnson et al., 2010). Amnestic MCI cases are at a greater risk of developing AD (Petersen, 2004; Johnson et al., 2010). A significant proportion of elderly people clinically diagnosed with NCI or with MCI display amyloid plaque and NFT pathology similar to that seen in AD, challenging the pathologically-based concept that these lesions alone hasten dementia onset (Mufson and Kordower, 1999; Price and Morris, 1999; Markesbery, 2010; Mufson et al., 2016a,b).

CLASSIC AD LESIONS

By the twentieth century, neuropathological investigations reported the existence of abnormal extracellular plaques in brains obtained postmortem from older adults with dementia (Blocq and Marinesco, 1892). The German psychiatrist, Dr. Alois Alzheimer, treated Auguste Deter, a 51-year old woman, who presented with signs of paranoia and memory impairment and died 5 years after diagnosis. At autopsy, her brain appeared atrophic, with a loss of neurons, and contained NFTs and senile plaques (SPs). Dr. Emil Kraepelin termed this triad of features “Alzheimer’s disease.” SPs found in the extracellular matrix consist of insoluble fibrils of Aβ, produced from a larger transmembrane amyloid-β precursor protein (APP) by the successive cleavage by the β-site APP cleaving enzyme 1 (BACE1) and the intramembrane γ-secretase complex (Shoji et al., 1992; Thinakaran and Koo, 2008). NFTs consist of intracellular aggregates of hyperphosphorylated tau protein (Trojanowski et al., 1993; Yoshiyama et al., 2013). Although SPs and NFTs are considered the defining pathological hallmarks of AD, Dr. Alzheimer wrote that “…the plaques are not the cause of senile dementia, but only an accompanying feature of senile involution of the central nervous system” (Alzheimer, 1911). Despite this statement, the AD research field has been driven by the “amyloid cascade hypothesis” (Hardy and Selkoe, 2002) and treatment strategies continue to revolve around the development of anti-amyloid drugs to remove plaque deposition. However, virtually all anti-amyloid clinical trials have not met their primary end-point, the improvement of cognition (Hampel et al., 2015, 2018). This lack of drug efficacy lends support to the concept that amyloid may be an early biomarker of AD but not necessary for a clinical decline. More likely AD is a multifaceted polygenic disease of which amyloid is a partner in the pathogenesis of this disease. Contrary to the amyloid hypothesis, a large body of literature suggests the loss of cognition involves the selective vulnerability of multiple neurotransmitter pathways leading to a massive cortical disconnection syndrome.

CHOLINOTROPHIC BASAL FOREBRAIN DEFECTS DURING THE PROGRESSION OF AD

For over 30 years degeneration of cholinergic basal forebrain (CBF) neurons, which innervate the entire neocortex and hippocampus (Figures 2A–D) has been investigated as a key neurotransmitter system affected early in the disease that may be a target for AD treatment (Hampel et al., 2018). The “cholinergic hypothesis” of AD (Bartus et al., 1982) gained momentum with the finding that acetylcholinesterase inhibitors (AChEIs) have significant symptomatic effects in AD patients (Summers et al., 1986) This led to the development of a larger family of acetylcholinesterase inhibitors (AChEIs) (Hampel et al., 2018) (Figures 2E–G), which remains one of the few classes of FDA approved drugs for the treatment of AD (Johannsen, 2006; Mangialasche et al., 2010; Hampel et al., 2018). For example, the AChEI, donepezil, has been shown to reduce basal forebrain atrophy within the nucleus basalis of Meynert (nBM) and the medial septum/diagonal band in prodromal AD, demonstrating a structural effect (Cavedo et al., 2017) as well as symptomatic relief.

Recently, there has been a resurgence of interest in the CBF projection system in the field of early-onset dementia (Douchamps and Mathis, 2017; Hampel et al., 2018). Imaging
studies provide evidence of the importance of dysregulated basal forebrain circuitry in signaling related to cognitive decline (Ballinger et al., 2016), dysregulation of the default mode network (DMN) critical for executive function, episodic memory (Nair et al., 2018), and propagation of cortical atrophy early in the evolution of the disease (Schmitz and Nathan Spreng, 2016), and as a pre-symptomatic biomarker for AD (Ho et al., 2008; Grothe et al., 2012). This renewed interest in cholinergic cortical projection neurons to the DMN and other cortical sites during the onset of AD underscores the critical need to understand the mechanistic factors underlying dysfunction of this projection system.

NERVE GROWTH FACTOR DURING THE PROGRESSION OF AD

Since Ramon y Cajal suggested that brain cells require “special food,” researchers have searched for growth-stimulating agents that play a role in neuronal survival (Henry, 1998). Levi-Montalcini and Cohen (Levi-Montalcini, 2000), received the Nobel Prize for their discoveries showing that the trophic substance nerve growth factor (NGF) underlies the selective survival of cultured neurons. They were the first to suggest the neurotrophic hypothesis of neuronal survival. NGF is a product of a single gene found on chromosome 1, which gives rise to a 27 kiloDalton (kDa) and a 35 kDa proNGF precursor protein (Francke et al., 1983; Edwards et al., 1988), which are proteolytically cleaved to a mature biologically active peptide (Edwards et al., 1988; Lee et al., 2001). ProNGF, not mature NGF, is the primary form found in the human brain (Fahnestock et al., 2001). NGF binds to its cognate tropomyosin-related kinase A (TrkA) receptor and the p75 pan-neurotrophin receptor (p75NTR) (Ibanez, 2002; Chao, 2003; Kaplan and Miller, 2004). NGF binding to TrkA activates downstream survival pathways by activating Akt (Ulrich et al., 1998) while proNGF and p75NTR, together with its co-receptors sortilin (Nykjaer et al., 2004) and neurotrophin receptor homolog-2 (NRH2) (Murray et al., 2004) activate the c-Jun N-terminal protein kinase (JNK) related to cellular apoptosis (Nykjaer et al., 2005) (Figure 3). Clinical trials have shown that NGF has therapeutic potential to enhance CBF survival and neuroplasticity in AD (Tuszynski et al., 1990; Tuszynski and Blesch, 2004; Tuszynski et al., 2015).

NGF AND THE PROGRESSION OF AD

Although for many years it was hypothesized that cholinotrophic basal forebrain cortical and hippocampal projection neurons degenerate due to loss of NGF in AD (Hefti and Mash, 1989; Tuszynski et al., 1990; Smith et al., 1999), studies reported unchanged (Goedert et al., 1989; Allen et al., 1991; Murase et al., 1993; Jette et al., 1994), decreased (Hellweg et al., 1998) or increased (Crutcher et al., 1993; Scott et al., 1995; Fahnestock et al., 1996; Narisawa-Saito et al., 1996; Hellweg et al., 1998; Hock et al., 2000) NGF levels using tissue from severe AD subjects. However, NGF levels were preserved in five cortical regions (superior frontal, superior temporal, middle temporal, anterior cingulate, and inferior parietal cortex) and hippocampus in people who came to autopsy with a clinical diagnosis of MCI, mild AD, and severe AD (Figure 4) (Mufson et al., 2003). In contrast, others report an increase in cortical and hippocampal Ngf mRNA and protein in end-stage AD, where volume loss...
could lead to increased concentrations of NGF per weight or volume (Crutcher et al., 1993; Jette et al., 1994; Scott et al., 1995; Fahnestock et al., 1996; Narisawa-Saito et al., 1996; Hellweg et al., 1998; Hock et al., 2000) or the translation from Ngf to encoded NGF protein may be compromised or expression levels differ between AD cases. We reported a wide range of NGF activity in a cohort ranging from early to late-onset AD cases and some of the highest and lowest levels of NGF were seen in end-stage AD cases (Scott et al., 1995), suggesting that within a given cohort, NGF levels can be differentially affected by age at disease onset or differences in disease process. In this study, there was no relationship between cortical choline acetyltransferase (ChAT) activity, the rate-limiting enzyme for acetylcholine synthesis, and levels of NGF, nor between reduced numbers of ChAT- (Gilmor et al., 1999), TrkA- (Mufson et al., 2000), or p75<sub>NTR</sub>- (Mufson et al., 2002b) containing neurons in MCI and mild AD. Moreover, the lack of a correlation between the apolipoprotein ε4 genotype and NGF levels is interesting, since ApoE ε3 and ε4 alleles are reported to be associated with a greater decrease in cholinergic markers in end-stage AD (Poirier et al., 1995). Although over 90% of the severe AD cases we examined from the Rush Religious Orders Study (RROS) contained at least one ApoE ε4 allele, NGF levels did not differ across the clinical groups evaluated (Mufson et al., 2003). These observations suggest that ApoE ε4 genotype does not directly affect the metabolism of NGF.

**EXPRESSION OF NGF RECEPTORS DURING THE PROGRESSION OF AD**

Cholinergic basal forebrain neuron function is dependent upon the binding of NGF to its cognate receptor TrkA, as well as its pan-neurotrophin p75<sub>NTR</sub>, which lends support to the suggestion that dysregulation of NGF and its receptors underlie cholinergic neuron dysfunction in AD. TrkA receptors and p75<sub>NTR</sub> are produced within the perikarya of CBF neurons and anterogradely transported to the cortex and hippocampus the sties of NGF production (Schwab et al., 1979). Within CBF neurons, mature NGF binds to the TrkA receptor, activating signal transduction pathways that regulate neuronal survival induced by NGF (Kaplan and Miller, 2004). However, p75<sub>NTR</sub> is a positive modulator of NGF/TrkA binding (Kaplan and Miller, 2004), and exhibits several context-dependent functions including the stimulation of apoptotic or cell death pathways (Bamji et al., 1998; Yoon et al., 1998; Frade, 2000;
In this regard, the specific downstream effects of p75NTR are dependent upon its interaction with various receptor chaperones (Mamidipudi and Wooten, 2002; Nykjaer et al., 2004; Teng and Hempstead, 2004).

In order to evaluate whether the number of CBF neurons containing NGF receptors is altered early in the progression of AD, we examined tissue from RROs subjects clinically categorized as NCI, MCI, or AD (Gilmor et al., 1999). Interestingly, the numbers of ChAT-containing neurons were stable in MCI and mild AD, while TrkA- and p75NTR-immunoreactive neurons were significantly decreased compared to NCI, indicating a phenotypic downregulation of receptors supporting CBF function rather than frank neuronal degeneration in MCI (Gilmor et al., 1999) (Figure 5). The phenotypic loss of cholinotrophic markers due to atrophy, rather than overt cholinergic cell loss, is consistent with animal model studies of septal cholinergic neuron axotomy via fimbra-fornix transection and excitotoxicity (Hefti, 1986; Williams et al., 1986; Ginsberg and Martin, 1998). In AD, reduced cortical TrkA levels positively correlated with lower cognitive performance as assessed by the Mini-Mental State...
FIGURE 5 | Histograms showing the differential reduction in cholinergic, TrkA and p75NTR immunoreactive neurons during the progression of AD. A1–C1. Photomicrographs of dual labeled nucleus basalis neurons showing phenotypic downregulation of p75NTR (dark blue) compared to ChAT (pink) positive neurons between no cognitive impairment (NCI), mild cognitive impairment (MCI) and AD. Note the loss of p75NTR immunoreactive staining of ChAT-positive cells in MCI and AD (open arrows). Black arrow indicates dual stained neuron in AD (C1), * and ** indicate p < 0.05 and 0.01, respectively.

Exam (MMSE) (Counts et al., 2004), suggesting that decreased nbM and cortical NGF receptor protein levels may mark the early onset of AD.

CORTICAL proNGF LEVELS DURING THE PROGRESSION OF AD

Alterations in proNGF, the NGF precursor protein, has received extensive study in clinical pathological investigation of components of the cortical DMN, which includes frontal cortex, posterior cingulate, precuneus, superior temporal cortex (Perez et al., 2015), and the hippocampus (Mufson et al., 2012b), which contribute to cognitive dysfunction during the progression of AD (Sperling et al., 2014). ProNGF isolated from AD cortex induces apoptosis in neuronal cell cultures by interacting with p75NTR via a mechanism dependent upon γ-secretase shedding of the receptor, whereas proNGF isolated from control brain does not activate apoptosis (Pedraza et al., 2005). ProNGF levels are increased in the lateral parietal cortex of patients who died with a clinical diagnosis of MCI or mild AD compared to those with NCI (Peng et al., 2004). In contrast, precuneus proNGF levels were stable until end-stage AD (Perez et al., 2015), similar to that of the frontal cortex (Fahnestock et al., 2001, 2004; Podlesniy et al., 2006) and hippocampus (Al-Shawi et al., 2008; Mufson et al., 2012b), all of which suggest alterations of proNGF in the diseased brain. Western blotting found no changes in the levels of TrkA, p75NTR and the co-receptor, sortilin within the precuneus (Perez et al., 2015), and hippocampus (Mufson et al., 2010) across clinical groups. ProNGF binds with a higher affinity to p75NTR, which is enhanced in the presence of sortilin to induce apoptosis (Lee et al., 2001; Nykjaer et al., 2004; Pedraza et al., 2005; Al-Shawi et al., 2008). Homeostatic regulation of NGF receptors, combined with the binding of proNGF to TrkA (albeit with less affinity than mature NGF), results in the activation of downstream pathways involved in CBF neuron function (Fahnestock et al., 2001, 2004) as well as the induction of neurotrophic activity via the binding with less affinity to the TrkA receptor (Fahnestock et al., 2001, 2004). The finding that p75NTR levels remain stable in the precuneus and other cortical regions (Counts et al., 2004; Mufson et al., 2012b) during the onset of AD may be related to the demonstration of a de novo appearance of p75NTR cortical neurons in AD (Mufson and Kordower, 1992).

The pro-apoptotic effect(s) of p75NTR-mediated proNGF signaling is dependent on interactions with p75NTR and sortilin, a Vps10p domain trafficking protein that acts as a cell surface co-receptor with p75NTR to mediate proNGF-activated cell death. This family of receptors is gaining importance, due to its potential involvement in AD (Nyborg et al., 2006). Sortilin activates p75NTR-induced apoptosis following proNGF treatment (Nykjaer et al., 2004), suggesting a role in cell death (Mamidipudi and Wooten, 2002; Roux and Barker, 2002). Blocking this binding event precludes binding of proNGF to p75NTR and subsequent cell degeneration (Bronfman and Fainzilber, 2004; Kaplan and Miller, 2004; Nykjaer et al., 2004; Teng et al., 2005). It is possible that p75NTR signaling in response to proneurotrophins depends upon the identity and...
efficacy of the bound co-receptor. Notably, cortical levels of sortilin remain stable, similar to p75NTR during the progression of AD. Perhaps pro-survival or pro-apoptotic signaling in CBF neurons is dependent upon changes in the stoichiometry of TrkA, p75NTR, the availability of select co-receptors, and the physiological role of proNGF within different milieus during the early stage of AD. Shifting the balance of these factors may change the response that proNGF binding activates within CBF neurons during the progression of AD (Figure 6). Defining these interactions will be key to the development of neurotrophic strategies for dementia (Bruno et al., 2004; Longo et al., 2007). If proNGF binds p75NTR in vivo and induces apoptosis (Lee et al., 2001; Nykjaer et al., 2004), it will be crucial to develop drugs that block proNGF binding to p75NTR. In contrast, if proNGF binds with TrkA to induce cell survival (Fahnestock et al., 2004), then the development of drugs that enhance this interaction could provide neuroprotection in AD.

NGF METABOLIC PATHWAYS DURING THE PROGRESSION OF AD

Defects in the metabolic pathways regulating the maturation and degradation of the NGF/proNGF complex may play a key role in CBF dysfunction. Recently, a protease cascade, which converts proNGF to mature mNGF and degrades mNGF in the extracellular space by the coordinated activity of plasminogen, tissue plasminogen activator (tPA), neuroserpin, matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) was shown to be defective in AD (Bruno and Cuello, 2006). In this regard, the upregulation of MMP-9 protein levels and activity were reported in the frontal and parietal cortex in MCI and AD, which was inversely associated with cognitive performance (Bruno et al., 2007), and may drive changes in NGF/proNGF activity (Figure 7). We suggest that increased proMMP-9 and MMP-9 compromises NGF support of CBF neurons during the transition from NCI to MCI (Figure 7). Interestingly, a similar increase in cortical proNGF (Iulita et al., 2014) and reduction in TrkA-positive CBF neurons (Sendera et al., 2000) has been reported in Down syndrome (DS), suggesting an overlap in NGF neurotrophic dysregulation in these disorders. Both AD and DS cases display cortical SP and NFT pathology and develop dementia by midlife (Mann and Esiri, 1989), further connecting these neurological conditions. It has been suggested that levels of metalloproteinases (MMPs) in blood, urine, and cerebrospinal fluid (CSF) may act as potential biomarkers for AD (Zucker et al., 1999; Lorenzl et al., 2003, 2008). It is of interest to examine whether or not MMPs are dysregulated in the precuneus, allowing for the stable metabolic NGF/proNGF complex regulation early in AD. Notably, proNGF levels were not associated with increased soluble Aβ1–42 or fibrillar Aβ [3H] Pittsburgh Compound B (PiB) binding, but instead with compact/pered-6-CN-PiB– positive plaques in AD (Perez et al., 2015), suggesting that fibrillar deposits of Aβ, rather than its soluble forms, may play a role in the upregulation of proNGF we found in the precuneus. Neurodegeneration is a consequence of Aβ1–40 binding to p75NTR (Knowles et al., 2009) and CBF perikarya when Aβ oligomers are delivered to the brains of wild type but not p75NTR deficient mice (Simmons et al., 2014). Interestingly, CBF degeneration was halted following the depletion of the neurotrophin-binding domain of p75NTR in a mouse model of AD.
AD (Knowles et al., 2009). These findings suggest that p75<sup>NTR</sup> signaling is involved in Aβ-induced degeneration and implicate it as an AD therapeutic target.

**HIPPOCAMPAL proNGF AND DOWNSTREAM PATHWAYS DURING THE PROGRESSION OF AD**

The hippocampus is a part of the mesial temporal lobe memory circuit. It develops extensive NFTs but lesser amyloid pathology in the early stages of AD (Hyman et al., 1984, 1990; Braak and Braak, 1991; Arriagada et al., 1992) and receives a major cholinergic input from the medial septal and vertical limb of the diagonal band neurons (Mesulam et al., 1983). Since these septohippocampal cholinergic projection neurons are also dependent upon NGF and its cognate receptors for their survival and degenerate in AD, studies were performed to determine alterations in the hippocampal NGF/proNGF system. Western blot analysis revealed a significant increase in hippocampal proNGF levels in AD but not MCI (Mufson et al., 2012b) in contrast to the neocortex (Bruno et al., 2009; Perez et al., 2015). Of interest is the observation of a significant reduction in TrkA protein levels in MCI hippocampus compared to NCI and AD and a return to NCI levels during the transition from MCI to AD (Mufson et al., 2012b) (Figure 8). The decrease in TrkA in the face of stable proNGF early in AD may enhance proNGF/p75<sup>NTR</sup>/sortilin/NRH2 binding, ultimately shifting the balance from pro-survival to pro-apoptotic signaling in the hippocampus (Figure 8). The upregulation of hippocampal TrkA levels is yet another example of human brain resilience (Mufson et al., 2016a,b) to slow disease progression.

Nerve growth factor and proNGF activate numerous downstream cell survival and apoptotic signaling pathways, respectively (Figure 8). The cell survival protein Erk, which is activated by TrkA phosphorylation, activates nuclear effectors involved in gene transcription (Zhu et al., 2001). Precuneus (Perez et al., 2015) and hippocampal (Mufson et al., 2012b) levels of total Erk, phospho-Erk, and phospho-Erk/Erk ratio are unchanged between NCI, MCI, and AD. In contrast, stress-activated kinase phospho-JNK, and the ratio of phospho-JNK to JNK were significantly increased in the AD precuneus (Figure 8) (Perez et al., 2015) and hippocampus (Mufson et al., 2012b), whereas total JNK levels were stable similar to the AD hippocampus (Mufson et al., 2012b). Bcl2 a component of the JNK signaling pathway involved in the activation of apoptotic enzymes was upregulated in the precuneus in AD but not MCI (Perez et al., 2015). Of particular interest was the finding that phospho-JNK and the density of AT8 tau-positive NFTs and neuropil threads (NTs) are positively related during the onset of AD, supporting the observation that JNK activation mediates tau phosphorylation at Ser202/Thr205 (AT8 site) (Goedert et al., 1997; Reynolds et al., 1997). Therefore, the activation of JNK pro-apoptotic signaling may play a role in episodic memory impairment in AD.

**CHOLINOTROPHIC BASAL FOREBRAIN NEURON GENE EXPRESSION DURING AD PROGRESSION**

The identification of the genetic signature of 'selectively vulnerable' CBF neurons compared to relatively spared neurons during the onset of AD is crucial for the development of transcriptionally aided drug design to target therapeutics to
intervene with the onset of AD. A transcriptionally-driven therapeutic approach may be more likely to preserve brain connectomes including the NGF dependent CBF system that plays a key role in the pathogenesis and onset of dementia, especially during early stages of the disease process (Mufson et al., 2012a). Studies comparing gene expression profiles of CBF neurons identified by p75NTR (Mufson et al., 1989) display a dysregulation of select synaptic-related markers (e.g., downregulation of synaptophysin and synaptotagmin 1 among others), protein phosphatases/kinases (e.g., downregulation of protein phosphatases 1 and 2 subunits and upregulation of cyclin-dependent kinase 5) along with endosomal–lysosomal markers (e.g., upregulation of lysosomal markers cathepsin D, rab4, rab5, and rab7) in MCI and AD compared to age-matched NCI subjects (Ginsberg et al., 2006a,b, 2010; Counts et al., 2011). Moreover, significant downregulation of TrkA, TrkB, and TrkC was seen in single CBF neurons microaspirated from the nbM of MCI and AD compared to NCI (Ginsberg et al., 2006b) (Figure 9A), consistent with observations in another vulnerable cell type, hippocampal CA1 pyramidal neurons (Ginsberg et al., 2000, 2010). These findings revealed an intermediate reduction in MCI with the greatest decrement in AD compared to NCI. Moreover, expressed sequence tagged cDNAs (ESTs) [i.e., ESTs targeted to both the extracellular domain (ECD) and tyrosine kinase (TK) domains of Trk receptors] were downregulated. A ‘step down’ dysregulation of Trk expression, may in part, underlie CBF neuron demise associated with the clinical presentation of AD. Supporting this concept is the finding that downregulation of TrkA was associated with several measures of cognitive decline, including the MMSE, a composite global cognitive score (GCS), Episodic, Semantic, Working Memory, Perceptual Speed, and Visuospatial domains as well as Braak NFT stage and neuritic plaque (NP) load within the basal forebrain and hippocampus (Ginsberg et al., 2006b, 2019). Hence, Trk gene expression defects may provide a molecular marker for the transition from MCI to frank AD (Ginsberg et al., 2019). In contrast, p75NTR transcript levels were stable in CBF neurons across the clinical diagnostic groups (Ginsberg et al., 2006b), which was an intriguing finding compared to the significant reduction of p75NTR-immunopositive nbM perikarya in MCI and AD compared to NCI (Gilmor et al., 1999). The discrepancy between p75NTR protein and transcript expression in CBF neurons suggests a disconnection between mRNA transcription and protein translation during disease onset. CBF single population observations in postmortem human brain tissues suggest a relative selectivity in the alteration of the family of cognate NGF receptors during the progression of AD, and that neurotrophic deficits precede or occur during the earliest stages of cognitive decline and neuropathology.

**CHOLINOTROPHIC NEURON TAU PATHOLOGY DURING THE PROGRESSION OF AD**

Coincident with altered neurotrophic factor dysfunction during disease progression, CBF neurons also develop intracellular tau inclusions that appear as globose NFTs as well as NTs in MCI and AD (Sassin et al., 2000; Mesulam et al., 2004; Wu et al., 2005; Vana et al., 2011). The human brain contains three isoforms of tau with three tandem repeats (3Rtau; Mapt1, Mapt3, and Mapt5) and three tau isoforms with four tandem repeats (4Rtau; Mapt2, Mapt4, and Mapt6). Custom-designed microarray evaluation of CBF neurons did not reveal changes in any of the six tau transcripts between AD, MCI and NCI subjects (Ginsberg et al., 2006a). However, a significant shift in the ratio of 3Rtau/4Rtau was observed with a decrease in 3Rtau expression relative to 4Rtau levels for all tau transcripts. Tau transcript data suggest a fluctuation
in gene dosage for 3Rtau and 4Rtau within CBF neurons in MCI and AD, which was not seen in normal aging (Ginsberg et al., 2006a).

Single neuron expression profiling investigations have addressed the extent to which levels of transcripts encoding neurotrophin receptors are altered in individual nbM neurons labeled for the pretangle marker pS422+, the late stage caspase-cleaved tau marker TauC3+ or pS422/TauC3+ compared to unlabeled neurons obtained from NCI, MCI, and AD cases provided by the RROS (Tiernan et al., 2018a). Quantitative analyses compared transcript signal intensities between clinical stages or between tau neuronal phenotypes. Comparison of transcript expression in pS422+ nbM neurons microaspirated from each clinical stage revealed no statistical differences (Figure 9B). However, when analyzed independent of clinical diagnosis, expression levels of key genes regulating neurotrophin receptor expression were altered as classified by a phenotypic transition from unlabeled to pS422+ to pS422+/TauC3+ to TauC3+ in nbM neurons (Figure 9C). Compared to unlabeled, pS422+ nbM neurons showed a significant downregulation of six mRNAs encoding the intracellular TK and extracellular ECD domains of the neurotrophin receptors TrkA (Ntrk1 TK, 50% downregulation; Ntrk1 ECD, 53%), TrkB (Ntrk2 TK, 45%; Ntrk2 ECD, 42%), and TrkC (Ntrk3 TK, 38%; Ntrk3 ECD, 35%) (Figure 9C). In addition, we found that these same transcripts are significantly downregulated in neurons containing the early pretangle tau antibody Tau Oligomeric Complex 1 (TOC1) (Counts, unpublished observations), lending support to the hypothesis that neurotrophic dysfunction occurs before frank NFT formation.

In contrast, transcript levels of the mRNA encoding the pan-neurotrophin receptor p75NTR (Ngfr) were not decreased until the appearance of TauC3. This expression data complements our stereologic finding demonstrating that TauC3 and p75NTR did not co-localize within the CBF at the protein level (Mufson et al., 2002b; Vana et al., 2011). Prior studies reported that Trk receptors expression levels are downregulated in nbM neurons in MCI and AD relative to NCI (Ginsberg et al., 2006b). On the other hand, it was found that Ntrk transcripts were downregulated by the phenotypic transition from nbM non-labeled to pS422+ neurons, whereas no difference was found in Ntrk expression in pS422+ neurons from NCI, MCI, and AD cases (Figure 9C).

We previously performed antibody immunostaining for TOC1 (Patterson et al., 2011; Ward et al., 2013) and p75NTR to quantify pretangle tau oligomeric assemblies, which most likely are the more neurotoxic species of tau (Berger et al., 2007; Maeda et al., 2007; Kopeikina et al., 2011; Lasagna-Reeves et al., 2012; Sahara et al., 2013) within CBF neurons during the progression of AD (Tiernan et al., 2018b). Here the number of p75NTR+/TOC1+ nbM neurons progressively increased from NCI to MCI to AD, whereas single TOC1+ nbM neurons were lower in NCI and MCI but increased in AD. A sub-analysis of p75NTR+, p75NTR+/TOC1+, and TOC1+ nbM neurons in NCI cases with a low Braak score (Stages I-II) compared to a high Braak score (Stages III-V) revealed a significant increase in the number of p75NTR+/TOC1+ dual-immunolabeled neurons in NCI-high pathology compared to NCI-low pathology cases. The reduction of p75NTR+...
nbM neurons was associated with poorer GCS and MMSE performance test scores. TOC1 primarily co-localized with pS422 in NCI, but the transition to MCI and AD was marked by a shift from TOC1+/pS422+ toward triple-labeled TOC1+/pS422+/MN423+ neurons, implying a specific, linear order of epitope occurrence in nbM cholinotrophic neurons during disease progression. This arrangement suggests that aberrant phosphorylation primes the tau protein toward additional phosphorylation and conformational events (Luna-Munoz et al., 2007; Bertrand et al., 2010) that facilitates oligomerization (Iqbal et al., 2013). Given the findings that prefibrillar tau pathology is related with molecular and cellular alterations within nbM neurons (Tiernan et al., 2016, 2018b), the appearance of prefibrillar oligomeric tau likely precedes cell loss. Evidence implicating tau pathology as a driver of neurotrophic dysfunction is seen in tau transgenic mice and tau-transfected neuronotypic cells, which display a downregulation of the trophic substance brain-derived neurotrophic factor (BDNF) (Rosa et al., 2016). On the other hand, NGF regulates tau turnover (Sadot et al., 1996) and post-translational modifications including phosphorylation, cleavage, and ubiquitination (Nuydens et al., 1997; Shelton and Johnson, 2001; Babu et al., 2005; Amadoro et al., 2011), suggesting that neurotrophic abnormalities initiate tau pathology within CB neurons (Canu et al., 2017). Moreover, the reduced microtubule-binding capacity of tau and/or the somatodendritic accumulation of tau may contribute to axonal degeneration and associated NGF/TrkA signaling dysregulation (Mufson et al., 2002a; Schindowska et al., 2008). Additionally, proNGF induces tau hyperphosphorylation in vitro via the enhanced activity of GSK3β (Shen et al., 2018). Based on these collective results future analysis of the potential interactions between aberrant tau metabolism and disrupted neurotrophic signaling in cholinotrophic nbM neurons (Capsoni et al., 2000).

CHOLINOTROPIC EPIGENETIC ALTERATIONS DURING THE PROGRESSION OF AD

Histone acetylation and deacetylation are also involved in CBF neuron function via their regulation of ChaT (Aizawa and Yamamura, 2010; Aizawa et al., 2012; Bekdash, 2016) indicating a potential role for epigenetics in neuronal selective vulnerability in AD. Evidence is growing that histone deacetylases (HDACs), epigenetic enzymes with deacetylase activity, located within the nucleus and cytoplasm of neurons play a role in AD pathogenesis (Ding et al., 2008; Guan et al., 2009; Xu et al., 2011; Cook et al., 2012; Graff et al., 2012). Several HDACs are related with cellular events dysfunctional in AD, including endoplasmic reticulum stress (HDAC4) (Shen et al., 2016), autophagy (HDAC6) (Pandey et al., 2007), mitochondrial transport (HDAC6) (Chen et al., 2010), tau hyperphosphorylation (HDAC6) (Ding et al., 2008) and Aβ and tau accumulation (SIRT1) (Julien et al., 2009; Lalla and Donmez, 2013). However, whether epigenetic dysregulation occurs in cholinotrophic nbM neurons remains under-investigated in AD.

Of the HDACs, HDAC2 has received extensive investigation due to a role in the modulation of transcripts involved in cognition via chromatin plasticity regulation (Dawson and Kouzarides, 2012; Graff and Tsai, 2013; Volmar and Claes, 2015). In this regard, a clinicopathological investigation revealed alterations in HDAC2-immunoreactive (ir) nuclei within nbM neurons during the onset of AD (Mahady et al., 2019). This study revealed that normally rounded HDAC2-ir nbM nuclei appeared ovoid, flattened, and eccentrically located within the soma in MCI, mild AD (mAD) and severe AD (sAD) (Figures 10A–H). HDAC2 nuclear intensity was significantly reduced in sAD compared to the other clinical groups examined (Figures 10D,H). Moreover, HDAC2-ir nuclear intensity was significantly reduced in mAD compared to the NCI and MCI groups (Figure 10I). This study further demonstrated that HDAC2 nbM nuclear intensity was not significantly different in NCI and MCI. The sAD nuclear area was significantly smaller than observed in NCI, MCI, and mAD (Figure 10J). In mAD, HDAC2-ir nuclei displayed significantly smaller area compared to NCI. HDAC2-ir nuclear intensity was found to correlate with working memory and a GCS (Mahady et al., 2019). A decline in the number of nbM p75NTR immunoreactive neurons decreased across disease stages and was related to a reduction in HDAC2 nuclear immunoreactivity (Mahady et al., 2019). Similarly, a reduction in HDAC2 nuclear immunoreactivity was inversely related to an increase in the number of AT8 pretangle-bearing nbM neurons. Quantitation of the intensity of HDAC2 nuclei revealed a significant reduction in non-tangle bearing p75NTR, positive neurons in mAD and sAD compared to NCI and MCI. NbM neurons triple-labeled for p75NTR, the pretangle maker AT8 or late-stage tau epitope, TauC3, displayed an even larger decrease in HDAC2 immunoreactivity in AD compared to non-tangle bearing p75NTR neurons at each disease stage (Mahady et al., 2019). Within-group analysis indicated HDAC2-ir was highest in non-tangle bearing cholinergic perikarya in each clinical group (Mahady et al., 2019). Interestingly, HDAC2 nuclear immunoreactivity was further decreased in HDAC2/AT8/Thioflavin-S or HDAC2/TauC3/Thioflavin-S neurons in MCI and mAD. These findings suggest that a reduction in HDAC2 expression occurs before the onset of fibrillar tau pathology and that this alteration is exacerbated by phosphorylated and conformational tau epitopes in nbM neurons during the progression of AD. Although ChaT mRNA expression and protein levels are epigenetically modulated by hyperacetylation of the core promoter region of the ChaT transcript (Aizawa et al., 2012), decreased HDAC2 nuclear levels were found within cholinergic nbM neurons in MCI, but significantly decreased ChaT nbM protein levels were seen only in AD (Mahady et al., 2019). These phenomena suggest that HDAC2 nuclear protein downregulation does not alter neuronal ChaT activity early in the disease process. Immunohistochemical analysis of HDACs in cortical cholinergic nbM projection sites demonstrated differential regional findings. For instance, although HDAC1 and HDAC2 are reduced in AD entorhinal cortex (Mastroeni et al., 2010), HDAC2, but not HDAC1 or HDAC3, are increased in hippocampal and entorhinal cortex neurons in AD compared to HDAC2 in control.
subjects (Graff et al., 2012). Western blots of frontal cortex revealed significant increases in HDAC1, HDAC3, HDAC4, and HDAC6 in MCI and mAD compared to NCI whereas HDAC2 levels remained stable (Mahady et al., 2018). These findings suggest that differential epigenetic regulation occurs across brain regions affected in AD.

**CHOLINOTROPHIC BIOMARKERS FOR THE PROGRESSION OF AD**

As discussed above, protein levels of proNGF are increased in postmortem neocortex (Peng et al., 2004) and hippocampus (Mufson et al., 2012b) of subjects who died with a clinical diagnosis of MCI or mild AD compared to NCI, respectively, which correlated with poorer antemortem cognitive test scores (Peng et al., 2004; Mufson et al., 2012b). These observations initiated an investigation of whether altered CSF levels of proNGF mark a transition from NCI to MCI and AD. Ventricular CSF (vCSF) was obtained postmortem from RROS participants and premortem lumbar CSF was collected from subjects clinically diagnosed as CDR 0 (no dementia), CDR 0.5 (MCI or very mild AD), or CDR 1 (mild AD) at the Washington University Knight AD Research Center (Counts et al., 2016). Quantitative western blotting of vCSF revealed a significant (50%) increase in proNGF levels in aMCI compared to NCI and a 70% increase in AD compared to NCI, which displayed a significant inverse relationship between increasing vCSF proNGF levels and cognitive deterioration (Counts et al., 2016). Lumbar CSF proNGF levels were significantly (30%) increased in CDR 0.5 and CDR 1 compared to CDR 0 cases. Although no difference in levels of Aβ₁₋₄₂, total tau, phospho-tau, or phospho-tau/Aβ₁₋₄₂ was found between groups, the ratio of total tau/Aβ₁₋₄₂ levels was 50% higher in CDR 1 compared to CDR 0 subjects. Ratios were calculated for proNGF/Aβ₁₋₄₂, proNGF/total tau, and proNGF/phospho-tau to determine if the inclusion of CSF proNGF levels improved the reliability of these biomarkers. Interestingly, proNGF/Aβ₁₋₄₂ levels were 50% higher in CDR 0.5 and CDR 1 compared to CDR 0, whereas proNGF/total tau and proNGF/phospho-tau were unchanged between groups, suggesting the inclusion of proNGF as a candidate biomarker will improve the diagnostic probability needed to identify people in the preclinical or prodromal stages of AD.

**NGF THERAPY AS A TREATMENT STRATEGY FOR AD**

Evidence derived from studies employing NGF as a treatment strategy to rescue the cholinotrophic cortical projection system has revealed some promising results regarding prevention of CBF neuron atrophy and a correction of behavioral deficits

![Figure 10](image-url)
resulting from experimental damage or normal aging (Hefti, 1986; Williams et al., 1986; Hartikka and Hefti, 1988; Hatanaka et al., 1988; Nabeshima et al., 1994; Burgos et al., 1995; Charles et al., 1996; Hummel and Weis, 2002). This evidence led to the concept that treatments that facilitate NGF would be beneficial in reversing cholinotrophic dysfunction in AD. However, examination of studies of early NGF systemic administration showed several weaknesses including bioavailability of the neurotrophin to reach target neurons, unregulated neurotransmitter release, hyperinnervation, sprouting of neurons, sympathetic stimulation, induction of antibodies, cachexia, and hyperalgesia (Sramek and Cutler, 1999; Jonhagen, 2000; McArthur et al., 2000; Apfel, 2001). However, after further testing in rat and non-human primate animal models (Gnahn et al., 1983; Hefti, 1986; Gage et al., 1989, 1990; Hefti et al., 1989; Higgins et al., 1989; Tuszynski et al., 1990, 1991, 1996; Blesch and Tuszynski, 1995) and taking into account past failures (e.g., poor drug delivery and unwanted systemic side effects), a Phase I clinical trial was undertaken to determine the utility of ex vivo NGF gene therapy for AD (Tuszynski et al., 2005). The goal was both to protect cholinergic neurons within the nbM from degeneration as well as augment the function of remaining cholinergic neurons by intracranial delivery of human NGF. During clinical trials, patients with AD, underwent NGF transcript therapy using ex vivo or in vivo gene transfer directed at the cholinergic neurons within the nbM. Degenerating nbM neurons were found to respond to NGF, with axonal sprouting toward the NGF source (Figure 11). Participants that had unilateral gene transfer displayed neuronal hypertrophy in the NGF-treated cholinergic nbM.

Moreover, patients that sustained adeno-associated viral vector (serotype 2)-mediated NGF gene transfer, displayed activation of cellular signaling and functional markers. Interestingly, nbM neurons that exhibited pathologic tau and those that were tau immunonegative both expressed NGF, indicating that tangle-bearing neurons can be infected with therapeutic genes, which activate cell signaling. No adverse effects related to NGF treatment were found in these studies. In summary, these findings revealed that degenerating neurons can respond to NGF with axonal sprouting, cell hypertrophy, and activation of functional markers. These studies demonstrated that NGF-induced sprouting persisted for 10 years post NGF gene transfer and that this therapy appears safe over long periods of time (Tuszynski et al., 2015). It should be kept in mind that these studies were not double-blind, placebo-controlled clinical trials. Further clinical investigation of gene therapy approaches is warranted.

### SMALL MOLECULE NEUROTROPHIN COMPOUNDS FOR TREATMENT OF AD

Small molecule partial agonist and antagonist activators of NGF receptors have been considered for the treatment of AD (Skaper, 2008). For example, a high-throughput screening assay of small-molecule agonists for TrkA identified gambogic amide, an alkaloid used in traditional Chinese medicine as a possible candidate (Jang et al., 2007). Gambogic amide binds selectively to TrkA (but not TrkB and TrkC), phosphorylates TrkA tyrosine residues, and activates the Akt and Erk TrkA-mediated NGF signaling pathways. Gambogic amide has been demonstrated to ameliorate excitotoxic damage and promote neurite outgrowth in PC12 cells and reduce kainic acid neuronal induced cell death in mice (Jang et al., 2007).

Several lines of evidence also point to the modulation of degenerative signaling promoted by p75<sup>NTR</sup> as a potential therapeutic target for AD. Through either its constitutive activity in the unliganded state, or via that stimulated by its proneurotropin (proNT) ligands, p75<sup>NTR</sup> promotes degenerative signaling mechanisms including activation of JNK, caspase, and RhoA (Casaccia-Bonnefils et al., 1996; Harrington et al., 2002; Troy et al., 2002; Ibanez and Simi, 2012; Coulson and Nykjaer, 2013) each of which likely contributes to AD-related degeneration (Figure 12). Crossing various AD mouse models with a p75<sup>NTR</sup> knockout mouse construct results in reduced neuronal degeneration (Soothibundhu et al., 2008; Knowles et al., 2009; Murphy et al., 2015). Multiple studies have identified genetic polymorphisms in the genes encoding p75<sup>NTR</sup>, proNGF, proBDNF, or p75<sup>NTR</sup> co-receptors including sortilin and SorCS2 that mediate proNT binding associated with increased AD risk (Cotza et al., 2008; Di Maria et al., 2012; Anastasia et al., 2013; Reitz et al., 2013; Andersson et al., 2016; Matyi et al., 2017). The first small molecule ligands found to interact with p75<sup>NTR</sup> and modulate its signaling were identified using an in silico screening strategy based on synthetic peptides modeled on the loop I domain of NGF and mutational analyses of neurotrophin ligands (Massa et al., 2006). Two prototype small molecule compounds, LM11A-31 and LM11A-24, were found to prevent neuronal

---

**FIGURE 11** (A) Nerve growth factor (NGF) immunolabeling shows the site of NGF gene delivery in the human nucleus basalis of Meynert (arrowhead) under the anterior commissure (ac). Scale bar = 525 µm. The patient received the injection 3 years previously. (B) p75<sup>NTR</sup> neurotrophin receptor immunolabeling shows basal forebrain cholinergic axons penetrating into the graft (between the parallel lines) in a linear fashion. Scale bar = 25 µm. (C) Nerve growth-factor-expressing neurons compared with less intense labeling in the nucleus basalis of Meynert neurons located 3 mm from the injection site (D). Scale bar in (C) = 100 µm and in (D) = 325 µm. Images reproduced from Tuszynski et al. (2015).
FIGURE 12 | Diagram showing the association between p75NTR and Alzheimer’s-related degenerative signaling networks. Aging, Aβ and other processes produce numerous changes in signaling pathways involved in neurite and synapse function and degeneration. Degenerative signaling promoted by p75NTR in either its unliganded state, or in response to proneurotrophin binding to p75NTR and its sortilin family co-receptors, and mediated through one or more receptor adaptors enables or promotes AD-related degenerative processes. LM11A-31, which interferes with proneurotrophin degenerative signaling and promotes supportive/survival signaling through p75NTR, reverses many of these AD-associated effects (indicated by •).

FIGURE 13 | Summary diagram showing the changes in the relative levels of NGF-related proteins in the cortex and hippocampus during the progression of AD.
death in cell culture conditions under which neuronal survival is dependent on the addition of neurotrophins. These small molecule ligands effectively acted as positive p75NTR modulators, inhibited proNGF-induced cell death (Massa et al., 2006) and blocked binding of proNGF to p75NTR (Tep et al., 2013). Under these conditions, small molecule ligands could be described as p75NTR ‘agonists.' LM11A-31 has been shown to stimulate recruitment of interleukin-1 receptor-associated kinase (IRAK) survival adaptor to p75NTR and to upregulate downstream NF-kB and Akt pro-survival signaling. Neurotrophic activity and signaling were absent in cultures using p75NTR−/− neurons or in the presence of p75NTR-ECD blocking antibody (Massa et al., 2006). LM11A-31 blocks proNGF-induced degenerative mechanisms in models of spinal cord injury (Tep et al., 2013), neurogenic bladder dysfunction (Ryu et al., 2018), and arthritis (Minnone et al., 2017).

Multiple preclinical studies indicate a role for small molecule modulation of p75NTR as a therapeutic approach for slowing progression of AD-related degenerative mechanisms. Intracellular signaling networks linked to p75NTR have substantial integration with degenerative signaling networks implicated in AD (Nguyen et al., 2014). In a model of AD in which cultured hippocampal neurons are exposed to Aβ oligomers, LM11A-31 and LM11A-24 inhibited the following Aβ-induced degenerative mechanisms: activation of calpain/cdk5, GSK3β, JNK c-Jun, p38 kinase, RhoA; excessive tau phosphorylation; and inactivation of Akt and CREB (Yang et al., 2008). These ligands also blocked Aβ-induced neuritic dystrophy and hippocampal long-term potentiation (LTP) impairment. In studies employing the hAPP1Lond/Swe AD mouse model, a once-daily administration of LM11A-31 over 3 months corrected behavioral deficits and inhibited neurodegenerative molecular and cellular pathology including tau phosphorylation and misfolding, neurite dystrophy, microglial activation and astrocyte activation (Knowles et al., 2013; Nguyen et al., 2014). However, there was no effect on lowering soluble Aβ or amyloid plaque levels, consistent with a mechanism in which modulation of p75NTR inhibits the ability of Aβ to promote neural degeneration including tau-related molecular degenerative events and synaptic failure. The ability of LM11A-31 to reduce measures of microglial activation in hAPP1Lond/Swe AD mice was confirmed using multiple markers of microglial activation as well as micro-PET imaging using a PET ligand directed to the translocator protein (TSPO) (James et al., 2017). In hAPP1Lond/Swe AD mouse studies employing treatment in late-stage, application of LM11A-31 resulted in a partial reversal of neural degeneration, perhaps indicative of a particularly robust biological effect (Simmons et al., 2014). Figure 12 summarizes the ability of the p75NTR modulator LM11A-31, which interferes with proNT degenerative signaling and promotes supportive/survival signaling through p75NTR, to inhibit/reverse AD degenerative mechanisms.

Based on in vivo preclinical studies, a modified formulation of LM11A-31, as a first-in-class compound directed against a novel target, was tested in a phase 1 trial in normal subjects and found to be safe. This compound is currently in a randomized, double-blinded, phase 2a exploratory endpoint trial in subjects with mild to moderate AD (NCT03069014). Treatment is administered via daily oral capsules for 6 months, and measurements at baseline and post-treatment include the following: cognitive testing with multiple batteries; MRI volumetric measures and FDG-PET imaging; and CSF AD core biomarkers along with biomarkers relevant to target engagement and mechanisms of action.

CONCLUDING COMMENTS

Figure 13 summarizes the relative changes of NGF upstream and downstream signaling pathways within the cortex and hippocampus during the progression of AD. A preponderance of data indicates that normative levels of NGF and its cognate receptors are required for the survival and maintenance of the cholinotrophic system. The preservation of cholinergic nbM neurons in the face of reduced numbers of TrkA and p75NTR-positive neurons in MCI and mild AD indicates that there is not a frank loss of cholinergic perikarya per se but a phenotypic downregulation of receptor proteins early in the disease process. Both transcript and protein data indicate that CBF neuron dysfunction is associated with an imbalance between TrkA-mediated survival signaling and proNGF/p75NTR-mediated pro-apoptotic signaling. Despite these degenerative events, the cholinotrophic system is capable of cellular resilience and/or neuroplasticity during the prodromal (DeKosky et al., 2002) and even the later stages of the disease (Mufson et al., 2012b). In addition to neurotrophic dysfunction, alterations in nuclear epigenetic proteins occur within cholinotrophic nbM neurons during the progression of AD, particularly HDAC2, suggesting a mechanism associated with changes in transcript expression. Increased proNGF quantified in postmortem vCSF or premortem lumbar CSF marked the transition to MCI and to AD, suggesting that this proneurotrophin is a useful biomarker of disease progression. Clinical trials provide evidence that NGF gene therapy has the potential to be a treatment approach for the prevention of CBF degeneration in AD. Perhaps combining this therapeutic approach with the development of small molecule agonists to TrkA to facilitate prosurvival signaling (Jang et al., 2007) or small molecule antagonists to p75NTR for anti-apoptotic actions should be added to the treatment toolbox for MCI and AD.

AUTHOR CONTRIBUTIONS

EJM designed and wrote the manuscript. SEC, SDG, LM, SEP, SMM, FML, and MDI contributed text and editing of the manuscript.

FUNDING

Funded by grants PO1 AG014449, RO1 AG043375, PO1 AG107617, and P30AG053760 from the National Institutes of Health, the Alzheimer's Association, and Barrow and Beyond at the Barrow Neurological Institute. We are indebted to the Catholic nuns, priests, and lay brothers who participated in the Rush Religious Orders Study.
REFERENCES


Mufson et al. NGF Pathobiology in AD


Nd. Educ. 25, 225, 225.


Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., and Mufson et al. NGF Pathobiology in AD

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., and Mufson et al. NGF Pathobiology in AD


Conflict of Interest Statement: EJM consults for RegenBio. MDI discloses consultant fees at GE Healthcare. FML and SMM are listed as inventors on patents relating to LM11A-31, which are assigned to the University of North Carolina, University of California (UC), San Francisco and the Department of Veterans Affairs (VA). FML and SMM are entitled to royalties distributed by UC and the VA per their standard agreements. FML is a principal of, and has a financial interest in PharmatrophiX, a company focused on the development of small molecule applications. Conflict of Interest Statement: EMJ consults for RegenBio. MDI discloses consultant fees at GE Healthcare. FML and SMM are listed as inventors on patents relating to LM11A-31, which are assigned to the University of North Carolina, University of California (UC), San Francisco and the Department of Veterans Affairs (VA). FML and SMM are entitled to royalties distributed by UC and the VA per their standard agreements. FML is a principal of, and has a financial interest in PharmatrophiX, a company focused on the development of small molecule applications. EMJ consults for RegenBio. MDI discloses consultant fees at GE Healthcare. FML and SMM are listed as inventors on patents relating to LM11A-31, which are assigned to the University of North Carolina, University of California (UC), San Francisco and the Department of Veterans Affairs (VA). FML and SMM are entitled to royalties distributed by UC and the VA per their standard agreements. FML is a principal of, and has a financial interest in PharmatrophiX, a company focused on the development of small molecule applications. Conflict of Interest Statement: EJM consults for RegenBio. MDI discloses consultant fees at GE Healthcare. FML and SMM are listed as inventors on patents relating to LM11A-31, which are assigned to the University of North Carolina, University of California (UC), San Francisco and the Department of Veterans Affairs (VA). FML and SMM are entitled to royalties distributed by UC and the VA per their standard agreements. FML is a principal of, and has a financial interest in PharmatrophiX, a company focused on the development of small molecule applications. Conflict of Interest Statement: EJM consults for RegenBio. MDI discloses consultant fees at GE Healthcare. FML and SMM are listed as inventors on patents relating to LM11A-31, which are assigned to the University of North Carolina, University of California (UC), San Francisco and the Department of Veterans Affairs (VA). FML and SMM are entitled to royalties distributed by UC and the VA per their standard agreements. FML is a principal of, and has a financial interest in PharmatrophiX, a company focused on the development of small molecule applications. Conflict of Interest Statement: EJM consults for RegenBio. MDI discloses consultant fees at GE Healthcare. FML and SMM are listed as inventors on patents relating to LM11A-31, which are assigned to the University of North Carolina, University of California (UC), San Francisco and the Department of Veterans Affairs (VA). FML and SMM are entitled to royalties distributed by UC and the VA per their standard agreements. FML is a principal of, and has a financial interest in PharmatrophiX, a company focused on the development of small molecule applications.